PCA3 and prostate cancer: Notably, despite the increasing number of publications about the putative utility of circulating non-coding (ncRNAs) as clinical biomarkers, urinary lncRNA PCA3 is the only circulating RNA approved by the FDA for molecular testing and used to complement PSA for management of early prostate cancer [44].